Skip to main navigation

Our Science
Pipeline & Programs
About Us
Life at Arvinas
Patients
Investors + Media

>> Sub navigation

Careers
Contact

Investors + Media: Press Releases

Press Releases

Year

August 4, 2020

Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update

June 29, 2020

Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors

June 17, 2020

Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference

June 11, 2020

Arvinas Appoints Linda Bain to its Board of Directors

June 5, 2020

Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference

May 29, 2020

Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

May 20, 2020

Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders

May 13, 2020

Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer

April 28, 2020

Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update

April 13, 2020

Arvinas Provides Update on Business Continuity Related to the Impact of the COVID-19 Pandemic

Pagination

Current page 1
Page 2
Next page
Last page

Tools

Email Alerts
RSS Feeds
Print Page
Email Page

Leading the way in targeted protein degradation therapeutics.

Join our team of experts

Follow Us https://www.linkedin.com/company/arvinas/ https://twitter.com/ArvinasInc

©2020. All Rights Reserved.

Contact Privacy Policy Terms & Conditions